UNSPSC 51293601: Roxindole

This classification denotes a serotonin agonist and dopamine agonist with the molecular formula C23H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43227SMS0O, chemically known as 3-(4-(3,6-dihydro-4-phenyl-1(2h)-pyridinyl)butyl)-1h-indol-5-ol but generally known as roxindole, which bears US NIH Compound Identifier 219050. European Medicines Agency schedules Roxindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10399MIG.

UNSPSC 51293601 Roxindole, a Commodity code, shows limited alignment between its nominal scope and recent state and local procurement activity. The code appears designed for a specific pharmaceutical ingredient, yet the three most recent opportunities tagged under it span naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which directly involve roxindole. State and local buyers using this code are acquiring finished pharmaceutical products, drug deactivation systems, and pharmacy benefit administration services rather than roxindole as a raw material or active pharmaceutical ingredient. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), reflecting a mix of county-level and state-level health procurement.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline (note: the due date in the source is inconsistent with the posted date and appears erroneous), requiring quarterly deliveries to its Community Health Building in Sanford with all shipping included in vendor bids. The Texas HHS Commission posted a Request for Information on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by Minnesota's Department of Administration, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and 25 percent across administrative compliance, EDI capability, and fixed pricing. The code shows minimal recent relevant activity; procurement under this code appears mislabeled, and bidders should verify actual product scope before pursuing opportunities tagged to this UNSPSC number.